ong-term study of K-877 add-on to HMG-CoA reductase inhibitor in patients with dyslipidemia
Phase 3
- Conditions
- Dyslipidemia
- Registration Number
- JPRN-jRCT2080222021
- Lead Sponsor
- Kowa Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Dyslipidemia with high TG in treatment with HMG-CoA reductase inhibitor
Exclusion Criteria
Person who has severe liver disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TG percent change at the completion of treatment<br>Central laboratory test
- Secondary Outcome Measures
Name Time Method Percent changes of other lipid parameters at the completion of treatment<br>Central laboratory test